Safe Supply Streaming Co Ltd. Achieves U.S. Federal Vendor Registration and Secures Municipal Vendor Approval in Boca Raton, Florida
Toronto, Ontario--(Newsfile Corp. - March 10, 2026) - Safe Supply Streaming Co Ltd. (CSE: SPLY) (FSE: QM4) (OTCQB: SSPLF) ("Safe Supply" or the "Company") is pleased to announce that its wholly owned subsidiary, Safety Strips Tech Corp. ("Safety Strips"), has obtained a Unique Entity Identifier ("UEI") through the United States Government's System for Award Management (SAM.gov) and has received approved vendor status with the City of Boca Raton, Florida.
2026-03-10 7:03 AM EDT | Safe Supply Streaming Co Ltd.
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT
King of Prussia, Pennsylvania--(Newsfile Corp. - March 10, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on March 12th
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-03-10 7:00 AM EDT | Phio Pharmaceuticals Corp.
Hemostemix Leadership Attending Abundance360 Summit
Calgary, Alberta--(Newsfile Corp. - March 9, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) today announced that Thomas Smeenk CEO and Peter Lacey, Chairman are attending the 2026 Abundance360 Summit in Los Angeles this week. Founded by futurist and entrepreneur Peter H. Diamandis, the annual Abundance360 Summit convenes leading entrepreneurs, and investors, working at the frontiers of biotechnology, artificial intelligence, longevity science, and other exponential techn
Biotechnology, Pharmaceuticals, Health
2026-03-09 11:23 AM EDT | Hemostemix Inc.
Adia Med Unveils a Fresh Facelift: New Website by ZenChange Marketing Spotlights Cutting-Edge Regenerative Medicine Studies
Orlando, Florida--(Newsfile Corp. - March 9, 2026) - Adia Nutrition's (OTCQB: ADIA) subsidiary, Adia Med, has launched a complete digital refresh of its online presence. Through a strategic partnership with ZenChange Marketing, Adia Med has relaunched its website with a modern, streamlined design focused on transparency, accessibility, and clear information about its investigational studies. The update makes it easier for families, researchers, and healthcare professionals to explore the orga
Healthcare and Hospitals, Health
2026-03-09 9:38 AM EDT | Adia Nutrition Inc.
Defence Therapeutics Announces Closing of Private Placement of Units for Gross Proceeds of $9,595,000
Montreal, Quebec--(Newsfile Corp. - March 9, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the closing of a private placement (the "Private Placement") of 17,445,455 units (the "Units") at a price of $0.55 per Unit, for aggregate gross proceeds to Defence of $9,595,000.25. Each Unit is comprised
Biotechnology, Pharmaceuticals, Health
2026-03-09 3:15 AM EDT | Defence Therapeutics Inc.
Cosmo Pharmaceuticals Achieves 104.2M Revenue and 9.5M EBITDA in 2025; Proposes 2.10 Dividend; Establishes 2026 Growth Framework
Ad hoc announcement pursuant to Art. 53 LR Full Year 2025 revenue of €104.2 million, in line with guidance, with 85% recurring revenues Recurring revenues of €88.1 million, +15% year-over-year, reflecting structural business transformation EBITDA of €9.5 million, exceeding the upper end of guidance
Healthcare and Hospitals, Health
2026-03-09 2:00 AM EDT | Cosmo Pharmaceuticals N.V.
Apolo V Acquisition Corp. Announces Shareholder Approvals
Toronto, Ontario--(Newsfile Corp. - March 6, 2026) - Apolo V Acquisition Corp. (TSXV: AFV.P) ("Apolo" or the "Company"), a "capital pool company" pursuant to the policies of the TSX Venture Exchange (the "TSXV"), is pleased to announce the voting results from its Special Meeting of Shareholders (the "Apolo Meeting") held on Thursday, March 5, 2026 in connection with its previously announced proposed qualifying transaction (the "Qualifying Transaction"
Healthcare and Hospitals, Health
2026-03-06 9:08 AM EST | TelyRx
Mobile-health Network Solutions and Medpod Sign MOU to Advance AI-Driven, High-Fidelity Global Healthcare
Singapore, Singapore--(Newsfile Corp. - March 6, 2026) - Mobile-health Network Solutions (NASDAQ: MNDR) ("MNDR" or the "Company"), a leading AI-powered digital health platform, and Medpod Inc., a U.S.-based innovator in high-fidelity telediagnostics software and infrastructure, today announced the signing of a Memorandum of Understanding (MOU) outlining a strategic partnership to jointly expand intelligent, clinically robust healthcare access across global markets. Under the collaborati
2026-03-06 8:52 AM EST | Mobile-health Network Solutions
Tersis Technologies Names Hugo Mijares Chief Architectural Officer, Positioning for Future Infrastructure and Energy Development in Venezuela
Brooksville, Florida--(Newsfile Corp. - March 5, 2026) - Tersis Technologies (OTCID: TERS), a systems-focused energy and infrastructure company advancing regenerative solutions through practical integration, today announced the appointment of Hugo Mijares as Chief Architectural Officer. Mijares is the founder of ONE D+B MIAMI, a multidisciplinary design studio established in 2007 and known for its focus on material exploration, technical rigor, and architectural clarity. He earned his a
Agriculture, Energy, Alternative Energy, Health
2026-03-05 5:57 PM EST | Tersis Technologies Inc.
Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update
King of Prussia, Pennsylvania--(Newsfile Corp. - March 5, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeuti
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-03-05 4:05 PM EST | Phio Pharmaceuticals Corp.
Rapid Dose Therapeutics (DOSE) (RDTCF) Secures Patent for QuickStrip(TM) Nicotine Oral Film Targeting $38B Smoke-Free Nicotine Market
Burlington, Ontario--(Newsfile Corp. - March 5, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF), a Canadian biotechnology company specializing in oral thin film drug delivery technology, today announced the grant of a key patent for its QuickStrip™ Nicotine Bilayer Oral Film in partnership with Aavishkar Oral Strips. The patent, titled "Nicotine Bilayer Oral Film and Process for Preparation Thereof," has been granted by the Indian Patent Office under Patent Number
2026-03-05 10:08 AM EST | Rapid Dose Therapeutics Corp.
AliMed Launches New Line of Lightweight Hybrid Gel-Foam Positioners Aimed at Improving Safety for Patients and Staff
Dedham, Massachusetts--(Newsfile Corp. - March 5, 2026) - AliMed, LLC, a Massachusetts-based medical device manufacturer and distributor, is introducing its own line of innovative hybrid gel-foam positioners, expanding its broad portfolio of patient positioners. This unique design delivers the benefits of all-gel positioners with up to 50% reduction in weight. These new positioners are being sold under the name AliBlue™ L
Healthcare and Hospitals, Pharmaceuticals, Health
2026-03-05 10:00 AM EST | AliMed, LLC
BioHarvest Sciences Announces Board Transition and Appointment of Prof. Hezi Levy
British Columbia and Rehovot, Israel--(Newsfile Corp. - March 5, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology, today announced that Mr. David Tsur will step down from its Board of Directors after more than four years of service. The Company further announced the appointment of Prof. Hezi Levy to its Board of Directors, effective immediately. Mr. Tsur has served on BioHarvest's Board since 2021 and
Biotechnology, Pharmaceuticals, Health
2026-03-05 7:30 AM EST | BioHarvest Sciences Inc.
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - March 5, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-03-05 7:00 AM EST | Phio Pharmaceuticals Corp.
Cosmo Announces Strategic R&D Collaboration to Advance AI-Based Detection of Early Neoplasia in Barrett's Esophagus
Dublin, Ireland--(Newsfile Corp. - March 5, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced a strategic Research and Development Agreement with Amsterdam UMC and Eindhoven University of Technology to develop and clinically validate an artificial intelligence (AI)-based computer-aided detection (CADe) system for the identification of early neoplasia in Barrett’s esophagus. The collaboration represents an important step in ex
Healthcare and Hospitals, Health
2026-03-05 1:00 AM EST | Cosmo Pharmaceuticals N.V.
FDA Leadership Headlines at AAMI neXus 2026 Medtech Conference
Arlington, Virginia--(Newsfile Corp. - March 4, 2026) - The Association for the Advancement of Medical Instrumentation (AAMI) officially welcomes speakers from the U.S. Food and Drug Administration (FDA) to its upcoming medical device standards conference, AAMI neXus 2026. Dr. Michelle Tarver, Director of FDA's Center for Devices and Radiological Health (CDRH), w
2026-03-04 8:50 AM EST | Association for the Advancement of Medical Instrumentation
Safe Supply Confirms NIRLAB Drug Analysis Devices Actively Deployed and Under Field Evaluation by Government Stakeholders
Toronto, Ontario--(Newsfile Corp. - March 4, 2026) - Safe Supply Streaming Co Ltd. (CSE: SPLY) (OTCQB: SSPLF) (FSE: QM4) ("Safe Supply" or the "Company"), a pioneer in health, safety, and rapid response technologies, today provided an update on its NIRLAB SA ("NIRLAB") pilot program, confirming that NIRLAB NIRLIGHT spectroscopy drug analysis devices are currently deployed with government stakeholders and are being actively tested in the field. The Company is also reportin
2026-03-04 7:07 AM EST | Safe Supply Streaming Co Ltd.
Numinus Wellness Advises of a Change of Auditor
Vancouver, British Columbia--(Newsfile Corp. - March 3, 2026) - Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is advising of a change of its auditor. The Company's previous auditor, Horizon Assurance LLP ("Horizon") no longer serves as the Company's auditor, with PKF Antares Professional Corpora
2026-03-03 5:00 PM EST | Numinus Wellness Inc.
Adia Nutrition Announces Submission of Final Revised Protocol for Lower Back Pain Study with AdiaVita
Winter Park, Florida--(Newsfile Corp. - March 3, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a company focused on regenerative medicine and therapeutic solutions, today announced that its subsidiary, Adia Med of Winter Park, LLC, has submitted its final revised protocol to the Institutional Review Board (IRB) for the lower back pain clinical study.
Healthcare and Hospitals, Health
2026-03-03 10:20 AM EST | Adia Nutrition Inc.
Canadian Pulmonary Fibrosis Foundation: Oxygen Therapy Saves Lives and Health Care Dollars
Toronto, Ontario--(Newsfile Corp. - March 3, 2026) - Oxygen therapy is a lifeline for people living with chronic lung diseases like pulmonary fibrosis. It reduces hospitalizations and improves quality of life. Yet across Canada, access to medically necessary oxygen therapy depends on where a person lives, inconsistent qualification criteria and, in some cases, one's ability to pay. The Canadian Pulmonary Fibrosis Foundation (CPFF) is calling on health authorities to designate supplemental oxy
Healthcare and Hospitals, Health
2026-03-03 9:21 AM EST | Canadian Pulmonary Fibrosis Foundation